NBIX
$NBIX
Neurocrine Biosciences, Inc.
Neuroscience-focused biotech developing treatments for neurological and endocrine disorders.
HealthcareSubscribers
0
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
NBIX: Soleno Buyout Boosts Growth Outlook
Neurocrine Biosciences ($NBIX) is trading at $129.98 after announcing a $2.9B acquisition of Soleno Therapeutics that expands its obesity and rare-disease pipeline. Analysts remain constructive with a Strong Buy consensus and a mean price target around $178, implying roughly 37% upside.
Apr 6, 2026